Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ruxolitinib in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT03681561Phase 2Recruiting
- Start
- Sep 2018
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in classical Hodgkin lymphoma (cHL) (2 arms). Primary endpoints: Maximum Tolerated Dose at 24 months and Overall Disease Control at 24 months. Started Sep 2018; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03681561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681561.